RIMOXCLAMIN: New therapeutic regimen for Hansen’s Disease cure based on effective sensitivity recovery
The results indicate that RIMOXCLAMIN was superior to MDT/WHO in terms of quick recovery of neurological damage, evidenced by the improvement of symptoms and sensitivity in hands and feet as early as the third month, with a progressive improvement, maintained after the end of treatment, including a reduce of patients with PDG.
Authors
- Filipe Rocha Lima (ORCID: https://orcid.org/0000-0001-7629-4963)
- Marco Andrey Cipriani Frade (ORCID: https://orcid.org/0000-0003-2700-5971)
- Gustavo Sartori Albertino
- Helena Barbosa Lugão (ORCID: https://orcid.org/0000-0003-1623-7443)
- Wilson Marques (ORCID: https://orcid.org/0000-0002-4589-2749)
- Andrezza Telles Westin (ORCID: https://orcid.org/0000-0003-4256-208X)
- Natália Aparecida de Paula (ORCID: https://orcid.org/0000-0002-3744-8947)
- Fabiana Aparecida Correa Cinto
- Fernanda Cruz Perecin
Institutions
- Universidade de Ribeirão Preto (BR)
- Universidade de São Paulo (BR)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
Publication Details
- Journal
- The Brazilian Journal of Infectious Diseases
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1016/j.bjid.2025.104539
- Citations
- 2
- Primary Topic
- Leprosy Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79